Syntaxin, partnered with Allergan, announced the initiation of two Phase 2 studies of AGN-214868 for the treatment of patients with post herpetic neuralgia and overactive bladder. The trials will evaluate the safety and efficacy of this retargeted endopeptidase drug.

AGN-214868 is an endopeptidase drug candidate based on Syntaxin’s Targeted Secretion Inhibitors (TSI) technology. It is designed to selectively bind to its chosen targeted cells and become internalized to deliver endopeptidases into the cell’s cytoplasm, preventing further vesicular secretion. A single dose provides an extended duration of action from weeks to months.

For more information visit